Navigation Links
Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
Date:9/5/2007

's hospital, an investigator at the TIMI Study group and lead author of the study.

These data represent the first clinical report of the effect of ranolazine to reduce the incidence of cardiac arrhythmias and support the findings of many prior preclinical studies which have suggested that ranolazine has potential anti-arrhythmic properties due to its action as an inhibitor of the late sodium current.

In accordance with a special protocol assessment agreement between the U.S. Food and Drug Administration (FDA) and CV Therapeutics, the Company believes that data from the MERLIN TIMI-36 study could support expansion of the existing Ranexa indication to first line angina, and plans to submit a supplemental new drug application to the FDA in fall 2007. CV Therapeutics plans to ask the FDA to modify the existing product labeling for Ranexa by reducing cautionary language and expanding the indication to include first- line angina.

Ranexa is currently indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

Study Design

MERLIN TIMI-36 (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes) was a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of Ranexa during acute and long-term treatment in 6,560 patients (3,279 received ranolazine, 3,281 received placebo) with non-ST elevation ACS treated with standard therapy.

Within 48 hours of the onset of angina due to ACS, eligible hospitalized patients were enrolled in the study and randomized to receive intravenous Ranexa or placebo, followed by long-term outpatient treatment with Ranexa extended-release tablets or placebo. All patients also received standard therapy during both hospital-based and outpatient treatm
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Third coast of biotechnology makes strong showing at VC conference
2. Reforming FDA: Focus on safety, let market judge efficacy
3. Funds will support public safety communications interoperabilty
4. High interest forces delay in food safety symposium
5. Human factors and IT: Designing for patient safety
6. UW Medical Foundation CEO shares his vision on the state of health care and patient safety
7. UW symposium to explore impact of IT on improving quality, safety and cost of healthcare
8. Thompson receives leadership award for technology solutions for patient safety
9. Effects of Thermal Cycler Well-To-Well Temperature Uniformity on PCR Results
10. Measuring Gene Silencing Effects by RT-PCR Without RNA Isolation
11. Confirming RNAi Effects Is Now Easier Than Ever
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... April 21, 2015  Scientists from the J. ... organization, published a paper today outlining new synthetic ... called diatoms. The researchers, led by first author ... Philip Weyman , Ph.D., conclude that these ... of diatom genetics and thus facilitate advances in ...
(Date:4/21/2015)... , April 21, 2015 Merrimack Pharmaceuticals, ... from a multi-arm Phase 1 study of MM-141, a ... presented in an oral session by Dr. Mansoor ... Cancer Research Annual Meeting in Philadelphia, PA. ... of MM-141 as a monotherapy and in combination with ...
(Date:4/21/2015)... -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced ... April 23, 4:30 p.m. ET. Participants are invited to ... Investor call information: U.S./ Canada ... (925) 418-7845 Participant Passcode: 32888538 Questions can ... tina.amirkiai@fleishman.com . Access will be provided ...
(Date:4/21/2015)... 21, 2015  Cryoport, Inc. (OTCBB: CYRX) ... logistics solutions for the life sciences industry, ... lines, clinical research organizations, vaccine manufacturers and ... Mark W. Sawicki , Chief Commercial Officer, ... Summit in San Francisco, CA ...
Breaking Biology Technology:Scientists at the J. Craig Venter Institute Publish Paper Outlining Efficient Synthetic Biology Methods to Genetically Engineer Microalgae 2Scientists at the J. Craig Venter Institute Publish Paper Outlining Efficient Synthetic Biology Methods to Genetically Engineer Microalgae 3First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 2First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 3First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 4First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 5Ampio Announces Investor Call on Thursday, April 23, 4:30 p.m. ET 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 3
... Oct. 29 Vical Incorporated,(Nasdaq: VICL ) today ... three months and nine months ended September 30, 2008,before ... conduct a,conference call and webcast to discuss the financial ... on Wednesday, November 5. The call is,open on a ...
... Clearance from ... Development Progress Triggered $1M Milestone Payment from Cook Medical - ... 4:30 p.m. Eastern Time -, REDWOOD CITY, Calif., October 28 ... its fiscal 2009 first quarter ended September 30, 2008., "We had ...
... $490 Million, Up 14 Percent over Third Quarter 2007 ... Sales and Earnings Guidance, Introduces 2009 Adjusted Net ... Oct. 28 Cephalon, Inc. (Nasdaq:,CEPH) today reported third quarter ... for the third quarter of 2007, and at the high,end ...
Cached Biology Technology:Vical Announces News Release and Conference Call Schedule For Third Quarter 2008 Financial Results 2Vical Announces News Release and Conference Call Schedule For Third Quarter 2008 Financial Results 3Cardica Announces Fiscal 2009 First Quarter Financial Results 2Cardica Announces Fiscal 2009 First Quarter Financial Results 3Cardica Announces Fiscal 2009 First Quarter Financial Results 4Cardica Announces Fiscal 2009 First Quarter Financial Results 5Cardica Announces Fiscal 2009 First Quarter Financial Results 6Cephalon Reports Another Strong Quarter 2Cephalon Reports Another Strong Quarter 3Cephalon Reports Another Strong Quarter 4Cephalon Reports Another Strong Quarter 5Cephalon Reports Another Strong Quarter 6Cephalon Reports Another Strong Quarter 7Cephalon Reports Another Strong Quarter 8Cephalon Reports Another Strong Quarter 9Cephalon Reports Another Strong Quarter 10Cephalon Reports Another Strong Quarter 11Cephalon Reports Another Strong Quarter 12Cephalon Reports Another Strong Quarter 13Cephalon Reports Another Strong Quarter 14Cephalon Reports Another Strong Quarter 15Cephalon Reports Another Strong Quarter 16Cephalon Reports Another Strong Quarter 17Cephalon Reports Another Strong Quarter 18Cephalon Reports Another Strong Quarter 19
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/14/2015)... NEW YORK , April 14, 2015 /PRNewswire/ ... Fast IDentity Online (FIDO ® ) Alliance tm ... standards-based specifications. FIDO members commit to share technology ... authentication methods that are interoperable, more secure and ... specifications enable biometric identity verification that protects sensitive ...
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... researchers have discovered a novel molecular mechanism that can ... progression of some cancers. In the March 23 online ... scientists from the University of Montreal explain how they ... of inflammatory cytokines that normally activate the immune system, ...
... diagnosis is critical in treating Lyme disease. However, ... initially misdiagnosed because currently available serological tests have ... of infection. Misdiagnosed patients may go untreated and ... face longer and more invasive treatments, as well ...
... National Renewable Energy Laboratory (NREL) recently convened the ... with a mission to enable securitization of solar ... marketplace. SAPC,s primary efforts center on the ... documents relevant to residential and commercial deployment, and ...
Cached Biology News:University of Montreal researchers discover how drug prevents aging and cancer progression 2Penn Researchers attach Lyme disease antibodies to nanotubes, paving way for diagnostic device 2Penn Researchers attach Lyme disease antibodies to nanotubes, paving way for diagnostic device 3Penn Researchers attach Lyme disease antibodies to nanotubes, paving way for diagnostic device 4NREL assembles industry working group to advance solar securitization 2
5,6 Carboxyfluorescein is conjugated to BSA (bovine serum albumin) protein through amide bonds....
2,4,6-Trinitrophenyl hapten is conjugated to Bovine Serum Albumin protein through lysine by amide bonds....
... Edwards (1996) • Provides key ... immunoassays, including RIA, ELISA and ... the photoluminescent and chemiluminescent labels ... also given on assay design ...
EoProbe Eosinophil Staining Kit, 1 Kit...
Biology Products: